
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. holds a positive outlook due to its development of Z-endoxifen, which has demonstrated broad utility and encouraging efficacy across various breast cancer treatment settings, particularly showing favorable results in both ESR1 mutant and wild-type patients. The company's strategic focus on metastatic breast cancer (mBC) reflects valuable insights gained from interactions with regulatory advisors and key opinion leaders, positioning it well within the competitive oral selective estrogen receptor degrader (SERD) landscape. Furthermore, the ongoing development of additional therapeutic candidates, including drugs for COVID-19, provides further potential for significant growth and enhances the company's overall product pipeline.
Bears say
Atossa Therapeutics faces significant risks that negatively impact its stock outlook, including potential safety issues and lower-than-expected efficacy in its clinical programs, which could hinder progress and market acceptance. Furthermore, the company needs to secure approximately $275 million in additional financing by 2037, with a cash runway extending only into the second half of 2026, raising concerns about its financial sustainability. Additionally, the risk of delisting if the share price falls below $1, combined with increased competition and regulatory challenges, compounds the overall negative sentiment surrounding the company's future prospects.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares